Founded in 2017, Limelight Bio has developed proprietary technologies, advanced targets and leading drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches. The post Limelight Bio emerges with $75m to develop next generation gene therapies to overcome limitations of current treatments appeared first on Pharmaceutical Business review.
FKD Therapies Oy (FKD) has led the development and regulatory filing of nadofaragene firadenovec, which has been studied in 33 centers across the U.S. in collaboration with the The post FerGene’s phase 3 NMIBC study of Nadofaragene Firadenovec meets primary endpoint appeared first on Pharmaceutical Business review.
Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (NKF), its majority shareholder. Enoxaparin had annual sales of approximately $616M in The post Meitheal Pharmaceuticals announces FDA approval of Enoxaparin Sodium Injection, USP appeared first on Pharmaceutical Business review.
The company has completed the submission of a new drug application (NDA) to the regulator for fostemsavir. Fostemsavir, an investigational prodrug of temsavir, is a first-in-class HIV-1 attachment The post ViiV Healthcare seeks FDA approval for fostemsavir to treat HIV-1 infection appeared first on Pharmaceutical Business review.
Gatehouse Bio’s ‘sRNAlytics platform’ identifies novel small RNA (sRNA) signatures and illuminates molecular pathways correlated to and potentially driving disease. “Our annotation library of over 1.4M small RNA The post Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery appeared first on Pharmaceutical Business review.
This enterprise-wide data and analytics platform is expected to form the foundation for custom solutions powered by AWS AI and ML services to help drive agility, innovation, and The post AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations appeared first on Pharmaceutical Business review.
GvHD is a potentially life-threatening medical complication, which can affect patients receiving such transplants to treat certain genetic diseases and haematologic cancers. Orencia is an immunomodulator that disturbs The post Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD appeared first on Pharmaceutical Business review.
The transaction has been taken up by AstraZeneca as the compound patent protection of the two drugs is no longer valid in the two countries. It would also The post AstraZeneca sells US, Canada rights of Seroquel drugs to Cheplapharm appeared first on Pharmaceutical Business review.
Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review The post Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS appeared first on Pharmaceutical Business review.
The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties. IONTAS’ The post IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets appeared first on Pharmaceutical Business review.